Notably, a dramatic reduction in PD-L1 by ATXN3 deletion was detected in both LLC1 (more than 90% reduction) and B16 (more than 50% reduction) syngeneic tumors, indicating that ATXN3 plays a critical role in controlling PD-L1 expression in tumor microenvironment. The gene discussed is ATXN3; the disease is neoplasm.